1. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary 
Terry A. Jacobson, MD, Matthew K. Ito, PharmD, Kevin C. Maki, PhD, Carl E. Orringer, MD, Harold E. Bays, MD, Peter H. Jones, MD, James M. McKenney, PharmD, Scott M. Grundy, MD, PhD, Edward A. Gill, MD, Robert A. Wild, MD, PhD, Don P. Wilson, MD, W. Virgil Brown, MD 
Journal of Clinical Lipidology 
Volume 8, Issue 5, Pages (September 2014)
DOI: /j.jacl
Copyright © 2014 National Lipid Association Terms and Conditions

2. Figure 1
Model of steps in lifestyle therapies. ∗For people at high or very risk for ASCVD in whom drug therapy is indicated, it may be started concomitantly with lifestyle therapies. For other patients, a trial of lifestyle therapies should be undertaken before initiation of drug therapy. †In most cases, goal levels should be achieved in approximately 6 months. RDN, registered dietitian nutritionist.
Journal of Clinical Lipidology 2014 8, DOI: ( /j.jacl )
Copyright © 2014 National Lipid Association Terms and Conditions

3. Figure 2
Progression of atherogenic cholesterol-lowering drug therapy. ∗A moderate- or high-intensity statin should be first-line drug therapy for treatment of elevated levels of atherogenic cholesterol, unless contraindicated. In a patient with very high triglycerides (≥500 mg/dL), a triglyceride-lowering drug may be considered for first-line use to prevent pancreatitis. Other atherosclerotic cardiovascular disease risk factors should be managed appropriately in parallel. †In most cases, goal levels should be achieved in approximately 6 months.
Journal of Clinical Lipidology 2014 8, DOI: ( /j.jacl )
Copyright © 2014 National Lipid Association Terms and Conditions